General Information of Drug Combination (ID: DC39677)

Drug Combination Name
T-3.5 MK-4815
Indication
Disease Entry Status REF
Hepatoblastoma Investigative [1]
Component Drugs T-3.5   DM3Q1HL MK-4815   DMT9K74
N.A. N.A.
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: HB3
Zero Interaction Potency (ZIP) Score: 9.024
Bliss Independence Score: 13.598
Loewe Additivity Score: 2.085
LHighest Single Agent (HSA) Score: 3.512

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
DD2 DCCCO03 DD2 Investigative [3]
------------------------------------------------------------------------------------

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
3 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.